SomaLogic said after the close of the market on Monday that its second quarter revenues grew 45 percent year over year.

Agilent Technologies Inc. (NYSE: A) today reported revenue of $1.67 billion for the third quarter ended July 31, 2023, a decrease of 2.7% compared to the third quarter of 2022 and a decrease of 2.3% on a core(1) basis.

China Association of In Vitro Diagnostics (CAIVD) and In Vitro Diagnostics Society of China Association for Medical Devices Industry jointly compiled this report.

Roche subsidiary Foundation Medicine announced on Monday that its FoundationOne CDx test received approval from the US Food and Drug Administration for use as a companion diagnostic for Janssen Biotech's Akeega (niraparib and abiraterone acetate).

Thermo Fisher Scientific Inc. (NYSE: TMO) (“Thermo Fisher”), the world leader in serving science, today announced that it has completed the acquisition of CorEvitas, LLC (“CorEvitas”), a leading provider of regulatory-grade, real-world evidence for approved medical treatments and therapies, from Audax Private Equity (“Audax”), for $912.5 million in cash. Thermo Fisher announced the agreement to acquire CorEvitas on July 6, 2023.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the second quarter ended June 30, 2023.

MGI Tech reported on Friday that its first-half 2023 sequencing revenues rose 40 percent while total revenues dropped 39 percent.

ChromaCode on Thursday announced a partnership with cancer diagnostic laboratory Protean BioDiagnostics to launch a test for non-small cell lung cancer through an early access program.

GeneDx Holdings Corp. (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today reported its financial results for the second quarter of 2023.

Cue Health Inc. ("Cue") (Nasdaq: HLTH), a healthcare technology company, today reported financial results for the second quarter 2023.

Illumina (ILMN) came out with quarterly earnings of $0.32 per share, beating the Zacks Consensus Estimate of $0.02 per share. This compares to earnings of $0.57 per share a year ago. These figures are adjusted for non-recurring items.

This report is jointly prepared by China Association of In-Vitro Diagnostics and In Vitro Diagnostics Society of China Association for Medical Devices Industry.

QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, today announced financial results for the second quarter ended July 2, 2023.

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced results for the second quarter and first half of 2023.